Clinical Trials Study
Copyright ©The Author(s) 2021.
World J Diabetes. Mar 15, 2021; 12(3): 278-291
Published online Mar 15, 2021. doi: 10.4239/wjd.v12.i3.278
Table 1 Basic information of participants in the study
Condition
DON
HCs
t
P value1
Male/female10/1210/12N/A> 0.99
Age (years)54.74 ± 5.9853.02 ± 5.120.2740.914
Weight (kg)65.32 ± 7.5262.12 ± 8.570.1970.943
Handedness22R22RN/A> 0.99
Duration of DON (days)56.76 ± 5.26N/AN/AN/A
Best-corrected VA-left eye0.35 ± 0.221.05 ± 0.25-3.5810.014
Best-corrected VA-right eye0.26 ± 0.191.05 ± 0.15-3.1270.011
Latency (ms)-right of the VEP121.01 ± 10.64101.23 ± 5.423.2910.002
Amplitude (UV)-right of the VEP6.96 ± 2.1513.29 ± 1.84-8.0210.003
Latency (ms)-left of the VEP110.42 ± 7.48100.76 ± 3.295.5970.012
Amplitude (UV)-left of the VEP10.26 ± 3.3416.24 ± 2.65-3.0180.005